Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting

Core Viewpoint - Helix BioPharma Corp. has successfully closed a non-brokered private placement of 2,222,333 common shares at a price of $0.75 per share, raising gross proceeds of $1,666,750, as part of its bridge financing strategy to secure larger institutional investments [1][2]. Group 1: Private Placement Details - The recent private placement follows a previous one of $3,000,000 announced on January 9, 2025, marking the second phase in Helix's financing strategy [2]. - The net proceeds from this private placement will be allocated towards near-term development activities and working capital [2]. - The offering is subject to final approval from the Toronto Stock Exchange, with a hold period of four months and one day expiring on December 23, 2025 [2]. Group 2: Company Overview - Helix BioPharma is focused on developing innovative solutions for hard-to-treat cancers, with its pipeline led by Tumor Defense Breaker™ L-DOS47, which is designed to enhance the effectiveness of existing cancer therapies [5]. - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its foundation with Helix's next-generation bi-specific antibody-drug conjugates currently in discovery [5]. - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [5].